Latest News
Health Canada approves AbbVie's eight-week MAVIRET regimen for acute and chronic hepatitis C
6 January 2026 - US-based pharmaceutical company AbbVie Inc. (NYSE: ABBV) said on Tuesday that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for the treatment of acute and chronic hepatitis C virus infection in adults and paediatric p...
Day One completes Mersana acquisition to add rare cancer antibody drug conjugate
6 January 2026 - US-based biopharmaceutical company Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) announced on Tuesday that it has completed its acquisition of Mersana Therapeutics, Inc. (NASDAQ: MRSN), expanding its oncology pipeline.The deal adds...
Cartography Biosciences partners with Pfizer to discover tumour-selective antigens
6 January 2026 - Biotechnology company Cartography Biosciences Inc announced on Tuesday that it has entered a multi-year collaboration with biopharmaceutical company Pfizer Inc (NYSE:PFE) to discover tumour-selective antigens.Under the agreement, Car...
BostonGene and AstraZeneca collaborate to advance AI-driven oncology development
6 January 2026 - Biomedical software company BostonGene Corporation announced on Tuesday that it has agreed a strategic collaboration with biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) to advance oncology drug development...
Nimbus Therapeutics partners with Lilly to develop oral obesity treatment
6 January 2026 - Drug discovery company Nimbus Therapeutics LLC on Tuesday announced a multi-year research collaboration and exclusive worldwide license agreement with pharmaceutical company Eli Lilly and Company (NYSE:LLY) to develop a novel oral tr...